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Abstract 
Purpose: To develop a hirudin therapeutic protein that eliminates unwanted immune response. 
Methods: Molecular dynamic simulation was performed on immunodominant hirudin epitopes 1-15 and 
13-27 and its analog, modified peptide ligands (MPLs), namely, [Lys4] Hir1-15 and [Gly9] Hir1-15, [Gly21] 
Hir13-27 and [Lys21] Hir13-27. The selected epitopes were modeled and 20 ns of molecular dynamics 
simulation was performed on peptide-HLA1 0101 and MPLs-HLA1 0101 complexes to gain a better 
understanding of molecular recognition mechanisms of MHC peptide binding. Characterization of the 
process was done by evaluation of root mean square deviation (RMSD) and total energy of binding.  
Result: All complexes of MPLs-HLA-DRB1 0101 showed thermodynamically unstable structure in 
comparison with native epitopes-HLA-DRB1 0101. The findings indicate that these analogs have 
different orientation in HLA grooves and are not available for suitable interaction with HLA-DRB1 0101.  
Conclusion: Altogether, the results show the potentials of predictive methods and molecular modeling 
in molecular mimicry of peptide-MHC interaction and provide insights into the binding characteristics of 
antigen presentation mechanism.  
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Hirudin is a polypeptide consisting of 65-66 
amino acids. It is produced in the salivary glands 
of the leech Hirudo medicinalis and is the most 
potent thrombin inhibitor known which is naturally 
occurring [1-3]. R-hirudin is the currently 
accepted treatment for patients with heparin-
induced thrombocytopenia, but a significant 
problem in the clinical use of hirudin is its 
immunogenicity [4]. Hirudin has been shown to 
induce T-cell-dependent IgG antibody responses 
when used as a therapeutic protein [5].  
 
Molecular dynamics (MD) simulation is a 
powerful technique, which provides a high 
resolution dynamic picture and has widespread 
use in modelling different biological molecular 
systems [6-8]. Previous MD simulations have 
been performed to investigate changes in 
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conformational dynamics of thrombin binding 
cleft, when complexed with a native hirudin, and 
its mutants with single amino-acid mutation 
(submitted article). In the present study, four 
epitopes derived from mutants of hirudin variant 
III (HV3), have been studied with regard to their 
respective immunogenicity potential. We used 
immunoinformatic tools to antigen identification 
and characterization for the development of the 
hirudin, and obtained a successful prediction of 
the peptide-MHC binding. We have performed 
MD simulation runs of 20 ns to investigate the 
structural and dynamical differences of HLA-
DRB1 0101 binding cleft, when complexed with a 
native peptide as well as the effect of single 
amino-acid mutation of the peptides.  
 
This study focused on HLA-DRB1 0101 peptide 
binding site region to characterize and 
emphasize the similarities and differences in 
binding properties by (a) calculating root mean 
square deviation (RMSD) and (b) binding free 
energy. HLA-DRB1 0101 was selected because 
this haplotype has been observed to have 




In silico analysis of protein sequences 
epitope selection 
 
In a previous study, hirudin sequence was 
analyzed using two epitope prediction programs: 
IEDB (http://www.iedb.org/), and ProPred 
(http://www.imtech.res.in/raghava/propred/). In 
summary, the affinities of hirudin sequence were 
evaluated for HLA-DRB1 0101.The ProPred 
results include predicted MHC Class-II binding 
regions (9-mers core regions) in hirudin 
sequence and the results of the IEDB include 
binding affinity scores for fifteen-amino acid 
epitopes. IEDB program uses a maximum affinity 
score of fifty, and any affinity values below this 
score are considered significant. The epitopes 
with the highest affinities for HLA-DRB1 101 
were selected. Fragments of fifteen amino acids, 
identified by the best alignment between the 
sequence of the entire protein and the epitopes 
previously selected were chosen [6,11,12].  
 
In silico mutations were performed for each 
position of the 9-mer binding core of the peptide, 
19 mutated structures were generated where 
each structure contained a mutation of the core 
residue to one of the other 19 amino acids. Thus, 
for each epitope 171 (19×9) mutated structures 
were generated that covered all possible amino 
acids at each of the core position of the peptide 
[8]. 
Molecular modeling methods 
 
The construction of the three-dimensional 
structures of the two selected epitopes (epitopes 
1-15 and 13-27) and modified epitopes (MPLs, 
[Lys4] Hir1-15 and [Gly9] Hir1-15, [Gly21] Hir13-27 and 
[Lys21] Hir13-27) was performed using comparative 
modeling, which is a technique that is used to 
construct three-dimensional protein structures 
based on structurally similar proteins that have 
an evolutionary relationship . The Modeller9v13 
[13] program was used to construct the three-
dimensional structures of the epitopes using a 
structural alignment between the target 
sequence and the region of similarity of the 
protein template (PDB code: 4HTC) [14]. The 
best model was selected based on its energy, 
and it was subjected to further 20 ns molecular 
dynamics using Gromacs 4.6.5 Software 
package [15]. Epitopes and the mutated peptides 
structures were minimized before they were 
subjected to binding free energy calculation. 
 
Molecular dynamics simulation 
 
The initial structure of epitopes and its mutants 
were obtained from homology modeling. To 
obtain the starting structure of the epitopes/MHC 
class II (DRB1*0101, PDB code: 1PYW) [16] 
complex for molecular dynamics (MD) simulation, 
the docking protocol consists of rigid-body 
docking, semi-flexible refinement stage and final 
refinement inexplicit solvent was performed [17]. 
All of the simulations and the analysis of the 
trajectories were performed with Gromacs 4.6.5 
software package using the Gromos 96 force 
field software package. Each starting structure 
was solvated with explicit water molecules in a 
periodic cubic box. GENION procedure of 
Gromacs was used to obtain a neutral system by 
replacing the water molecules with Na+ ions. For 
native epitopes, [Gly9] Hir1-15 and [Gly21] Hir13-27, 
3 Na+ ions were added, while 2 Na+ ions were 
added for [Lys4] Hir1-15 and [Lys21] Hir13-27.  
 
The native epitopes/DRB1*0101 and mutated 
epitopes/DRB1*0101 systems were first energy 
relaxed with 250000 steps of steepest-descent 
energy minimization without position restraints. 
The equilibration run was followed by a 20 ns MD 
run without position restraints. The equilibration 
of the trajectory was checked by monitoring 
RMSD with respect to the initial structure and the 
free binding energy. The electrostatic term was 
described with the particle mesh Ewald 
algorithm. LINCS algorithm was used to 
constrain all bond lengths. All simulations were 
performed at 300 K. The density of the system 
was adjusted during the first equilibration runs at 
NPT condition by weak coupling to a bath of 
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constant pressure (P0 = 1 bar, coupling time τP = 
1 ps). The time step of the simulation was 2 fs. 
Electrostatic interactions were calculated using 
the Particle Mesh Ewald (PME) summation 
scheme. The coulomb interactions and van der 
Waals were truncated at 1.0 nm. Every 10 steps 
the non-bonded pair list was updated and every 
2 ps conformations were stored. VMD, PyMOL 
and Gromacs analysis tools were used for 






The hirudin sequence obtained from the UniProt 
KB, was used to predict its promiscuous epitopes 
using two different prediction programs: ProPred 
and IEDB. These programs compared the 
submitted sequences to specific matrices for 
HLA-DRB1 0101, and predict the binding affinity 
of the epitopes for the HLAs-DRB1 0101.  
 
Five different epitopes predicted based on 
previous study were used in this research. In the 
present study two epitopes from the five epitopes 
(each epitope consisted of fifteen amino acids) 
were selected, because they showed a 
significant likelihood of binding to HLA-DRB1 
*0101.  
 
Although the programs are different and have 
different numerical results, we adopted cut-offs 
based on the significance of the affinities shown 
by each epitope. Each of the two programs used 
for epitope selection has a specific algorithm and 
was developed in different ways. However, these 
programs work similarly to predict the strength of 
the interaction of specific HLAs with proteins and 
identify epitopes that have greater interactions 
with this molecule. The epitopes that were 
obtained for specific HLADRB1*0101 from the 
two programs were analyzed simultaneously and 
aligned with the total protein sequence. The aim 
of this analysis was to combine the best results 
from the two programs and the final peptide was 
selected based on residues that were common 
between both programs. In ProPred, those 
epitopes that had scores above the default 
binding threshold were selected. For the IEDB 
program, those epitopes that had an affinity 
score below 20 were selected. Of the hirudin 
analyzed, two sequences containing fifteen 
amino acids were selected; these corresponded 
to the epitopes that were most strongly 
recognized by HLA-DRB1 0101.  
 
To determine their stability, the epitopes were 
modeled and evaluated. Based on previous 
study (submitted article) and more study in the 
present research two regions, 
I1TYTDCTESGQNLCL15 and 
L13CLCEGSNVCGKGNK27,  were chosen 
because these appeared to be the most 
promiscuous among the epitopes examined, and 
therefore, the most likely to be presented to 
lymphocytes during a human immune response.  
Furthermore, using the IEDB program, and 
based on in silico mutation of the peptide, 
mutated epitopes with less antigenicity were 
determined. Finally [Lys4] Hir1-15 and [Gly9] Hir1-15, 
[Gly21] and [Lys21] Hir13-27 were selected for 




Modeling of epitopes and new mutants of 
epitopes  
 
Homology models of selected epitopes and their 
mutants were constructed with the program 
MODELLER9v13. Hirudin variant II (PDB code: 
4HTC; similarity 89 % with Hirudin variant III) 
appeared the appropriate template for 
comparative modeling of epitopes and their 
mutants of HVIII. The alignment of HVII and 
epitopes were generated by ClustalW [19]. The 
10000 different models generated for each 
epitopes and mutants by MODELLER were 
carefully analyzed for energy value and RMSD. 
Among the models, which were quite similar with 
energy values, the model possessing the least 
RMSD value with the backbone atoms of HVII (~ 
0.02 Å for epitopes and mutants), was selected 
for further study. The quality of the folding was 
assessed by VERIFY-3D (http://psvs-1_4-
dev.nesg.org/ ), which evaluates the compatibility 
of a given residue in a certain three-dimensional 
environment.  
 
PROCHECK [20] analysis indicates that the 
quality of the Ramachandran plots (100 % of the 
residues in the allowed regions) were equivalent 
to those of the template structure. The 
superimposition of the modeled epitope 1 (Hir1-
15) and its mutants, epitope 2 (Hir13-27) and its 
mutants structures is reported in Fig. 1a, b and 
2a, b, respectively. 
 
The selected mutated epitopes were built with 
the N-terminal mutation, to form the new 
structures. This strategy was adopted to 
decrease the immune response, as well as to 
improve the side effects of these molecules. 
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Figure 1: Superimposition of hirudin native epitopes and modified epitopes modeled structures (ball and stick 
shape). (a) native epitope Hir 1-15 (I1TYTDCTESGQNLCL15) native residue Thr (ball and stick, mauve) and its 
analog modified peptide [Lys4] Hir 1-15 (ball and stick, cyan) (b) native epitope Hir 1-15 (I1TYTDCTESGQNLCL15) 
native residue Ser (ball and stick, yellow) and its analog modified peptide [ Gly9] Hir 1-15 (white) 
  
A          B  
 
Figure 2: Superimposition of hirudin native epitopes and modified epitopes modeled structures (ball and stick 
shape). (a and b) native epitope Hir13-27 (L13CLCEGSNVCGKGNK27) native residue Val (ball and stick, tan) and 
its analog modified peptides [Gly21] Hir 13-27  (white) and [Lys21] Hir 13-27 (cyan), respectively 
 
The X-ray crystallography data from HLA-DRB1 
010 (PDB code: 1PYW) were used to build a 
model of the complex peptide-HLA1 0101. The 
major focus of this study was on comparing the 
dynamic behaviors of native peptides of hirudin 
and its mutants with lower antigenicity in docked 
complexes with HLA-DRB1 0101. 
 
The energy minimization method avoids 
unfavorable atomic interactions and packing 
forces. Furthermore, the conformational behavior 
and the potential energy surface were evaluated 
carefully. The analysis of the torsion angles in 
the model, which was refined after the MD 
simulation, showed that this simulation did not 
cause serious distortions in the structures. The 
Ramachandran plot indicates that 100 % of their 
residues are in the allowed regions in all of the 
epitopes models and their peptide mutants 
notably, some of the molecules showed 
conformational changes that formed well-defined 
secondary structures after the MD calculation, 
compared with structures generated using 
comparative modeling. Other epitopes only 
exhibited small structural changes as a result of 
the MD simulation. 
 
During the molecular dynamics simulation, the 
backbone RMSD, which referenced the initial 
structure, varied more at the beginning of the 
dynamics simulation and just after reaching the 
equilibrium state. This result indicates that few 
structural changes occurred. However, structural 
variations still occurred throughout the course of 
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the simulation. These variations are 
characteristic of small peptides, which are very 
flexible and have various minimum energy 
states, indicating that these peptides can assume 
different conformations. This structural 
modification, in turn, is related to the short amino 
acid sequence, which tends to have a greater 
degree of freedom. The structural modification 
also contributes to the large deviations, as 
observed throughout the MD simulation in Fig 3a 
and b, results in a lack of interaction between the 
modified epitopes with the amino acid residues in 
HLA-DRB1 0101 in comparison with native 
epitopes. 
Although there was a variation of 2-3 Å on the 
average in the RMSD values, there was no 
ascendant behavior in the graphs, suggesting 
that these structures reach structural equilibrium 
despite the flexibility of these epitopes. In 
addition, the variation in the total energy of the 
epitopes and their mutants during the 20 ns 
simulations is presented in Fig. 4a for (Hir) 
epitope 1-15 and its analogs [Lys4] Hir 1-15 and 
[Gly9] Hir 1-15, in Fig. 4b for (Hir) epitope 13-27, 






Figure 3: Time evolution of (a) Backbone RMSD (root mean square deviation), this graph, was calculated using a 
simulation time of 20 ns for the trajectory of the production. Dynamics, (a) native epitope Hir 1-15 (red), [Lys4] Hir 1-
15 (blue) and [Gly9] Hir 1-15 (green), (b) native epitope Hir13-27 (DK red), [Gly21] Hir 13-27 (cyan) and [Lys21] Hir 13-27 
(pink). 
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In the studied systems, the mutations promote 
instability in the epitope and result into high and 
the more positive energy high of almost 10000-
25000 kcal/mol in comparison with the native 
epitopes. Again, this can be due to the lack of 




Studies based on the identification of potentially 
immunogenic epitopes of hirudin obtained from 
medicinal Leech, through rational design, have 
not only proven to be a promising strategy for 
safer protein development but have also have 
aided in the development and improvement of 
computer programs capable of generating 
accurate and reliable data [7,11,21]. Hirudin has 
intrinsic factors contributing to antibody 
formation. Promiscuous epitopes of this protein 
can stimulate significant proliferation of Th2 
lymphocytes, a fact that highlights the utility of 
this strategy in searching for potentially 
immunogenic epitopes [22,23].  
 
The advantage of identification of immune 
dominant epitopes is the ability to design safer 
protein which would stimulate cellular 
proliferation to a lesser extent and decrease 




Figure 4: Change in the total energy during the simulation of the production dynamics as a function of time. The 
simulation was run at 300 K with a simulation time of 20 ns for the different epitopes and its modified peptides, (a) 
native epitope Hir 1-15 (red), [Lys4] Hir 1-15 (blue) and [ Gly9] Hir 1-15 (green), (b) native epitope Hir13-27(DK red), 
[Gly21] Hir 13-27 (cyan) and [Lys21] Hir 13-27 (pink) 
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In a previous study 3D structure of complete 
native hirudin and its new mutants (selected 
based decreased antigenicity) were built, docked 
with thrombin (as receptor) and molecular 
dynamic simulation study was done. The results 
demonstrated that the new mutants were 
thermodynamically and structural stable 
(submitted article). But in this study the 3D 
structures of selected epitopes 1 (Hir 1-15) and 2 
(Hir 13-27) and their mutants were built and 
validated by molecular modeling tools, and the 
RMSD values of modeled epitopes equaled 0.02 
Å, In addition, the stereo chemical quality was 
analyzed by Ramachandran plot, which 
determines the distribution of the Ψ and Φ angle 
of the main chain. Ramachandran plot of the best 
epitopes model and their mutants indicated that 
all residues were located in the favored region.  
 
Finally, the best structures were refined by 
energy minimization and molecular dynamic 
simulations. The molecular dynamic studies of 
native epitopes-HLA-DRB1 0101 and MPLs-
HLA-DRB1 0101 showed energy and RMSD 
variation during the simulation. RMSD and 
energy analysis for the binding site epitopes 
showed that the binding groove is more stable 
when HLA-DRB complex with native epitopes in 
comparison with new mutant epitopes. Overall, 
these results indicate that new mutants have less 
propensity for binding to MHC groove and could 
be considered as safe proteins that have less 
tendency stimulate the immune system. The use 
of these approaches has also been shown to be 
an economically interesting strategy because it is 




Molecular dynamic analysis by computational 
tools is an important technique for antigen 
identification and characterization for the 
development protein therapeutics. The 
immunoinformatic tools used in the present study 
helps to identify and characterize epitopes to 
reduce the stimulation of the host immune 
system. The epitopes and their mutants showed 
similar structure to those observed in the native 
proteins; however, they have different 
thermodynamically stable structures. These 
studies could improve the prediction level of 
immunogenicity of native hirudin and its mutants, 
the induced cytokine profile and the antibodies 
that are generated.  
 
To the best of our knowledge, the method 
presented here is novel in predicting hirudin 
peptide binding to HLA-DRB1 0101 for the 
design of new mutants that decrease the 
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